Volume reduction of water samples to increase sensitivity for radioassay of lead contamination

The World Health Organisation (WHO) presents an upper limit for lead in drinking water of 10 parts per billion ppb. Typically, to reach this level of sensitivity, expensive metrology is required. To increase the sensitivity range of low-cost devices, this paper explores the prospects of using a volume reduction technique of a boiled water sample doped with Lead-210 (210 Pb), as a means to increase the solute’s concentration. 210Pb is a radioactive lead isotope and its concentration in a water sample can be measured with e.g. High Purity Germanium (HPGe) detectors at the Boulby Underground Germanium Suite. Concentrations close to the WHO limit have not been examined. This paper presents a measurement of the volume reduction technique retaining 99±(9)% of 210Pb starting from a concentration of 1.9×10−6 ppb before reduction and resulting in 2.63×10−4 ppb after reduction. This work also applies the volume reduction technique to London tap water and reports the radioassay results from gamma counting in HPGe detectors. Among other radio-isotopes, 40K, 210Pb, 131I and 177Lu were identified at measured concentrations of 2.83×103 ppb, 2.55×10−7 ppb, 5.06×10−10 ppb and 5.84×10−10 ppb in the London tap water sample. This technique retained 90±50% of 40K. Stable lead was inferred from the same water sample at a measured concentration of 0.012 ppb, prior to reduction

Characterization of germanium detectors for the first underground laboratory in Mexico

This article reports the characterization of two High Purity Germanium detectors performed by extracting and comparing their efficiencies using experimental data and Monte Carlo simulations. The efficiencies were calculated for pointlike γ-ray sources as well as for extended calibration sources. Characteristics of the detectors such as energy linearity, energy resolution and full energy peak efficiencies are reported from measurements performed on surface laboratories. The detectors will be deployed in a γ-ray assay facility that will be located in the first underground laboratory in Mexico, Laboratorio Subterr'aneo de Mineral del Chico (LABChico), in the Comarca Minera UNESCO Global Geopark [1]

Gamma-ray flux measurement and geotechnical studies at the selected site for the LABChico underground laboratory

No description supplie

Gender differences and management of stroke risk of nonvalvular atrial fibrillation in an upper middle-income country: Insights from the CARMEN-AF registry

Background: Atrial Fibrillation (AF) is associated with an increased risk of stroke and systemic embolism. Several studies have suggested that female AF patients could have a greater risk for stroke. There is scarce information about clinical characteristics and use of antithrombotic therapies in Latin American patients with nonvalvular AF. Objective: To describe the gender differences in clinical characteristics, thromboembolic risk, and antithrombotic therapy of patients with nonvalvular AF recruited in Mexico, an upper middle-income country, into the prospective national CARMEN-AF Registry. Methods: A total of 1423 consecutive patients, with at least one thromboembolic risk factor were enrolled in CARMEN-AF Registry during a three-year period (2014–2017). They were categorized according to Gender. Results: Overall, 48.6% were women, mean age 70 ± 12 years. Diabetes, smoking, alcoholism, non-ischemic cardiomyopathy, coronary artery disease, and obstructive sleep apnea were higher in men. Most women were found with paroxysmal AF (40.6%), and most men with permanent AF (44.0%). No gender differences were found in the use of vitamin K antagonists (VKA) (30.5% in women vs. 28.0% in men). No gender differences were found in the use of direct oral anticoagulants (DOAC) (33.8% women vs 35.4% men). Conclusions: CARMEN-AF Registry demonstrates that in Mexico, regardless of gender, a large proportion of patients remain undertreated. No gender differences were found in the use of VKA or DOAC. Keywords: Atrial fibrillation, Gender, Thromboembolic risk, Antithrombotic therapy, Stroke, Mexic